AI Designs a Novel PROTAC from Scratch: Insilico's generative AI platform, Chemistry42, successfully designed a first-in-class PROTAC targeting PKMYT1 by creating an entirely new inhibitor and its ...
A 3D virtual model of the PKMYT1–PROTAC–CRBN ternary complex depicting how Insilico Medicine’s bifunctional proteolysis-targeting chimera (PROTAC) D16-M1P2 (shown in yellow) inhibits ...
Veppanu represents a scientific milestone as the first-ever proteolysis-targeting chimera (PROTAC) to receive FDA approval.
Veppanu leverages PROTAC-mediated ubiquitin–proteasome degradation to eliminate mutant estrogen receptor, aiming to bypass ESR1-driven endocrine resistance rather than merely inhibiting receptor ...
From AstraZenecaReviewed by Megan Craig, M.Sc. This article and associated images are based on a poster originally authored by Camilla Ruffilli, Helen Boyd, Kevin Moreau and Noam Zelcer and presented ...
Association of genomic alterations with clinical outcomes following lutetium-177-PSMA vipivotide tetraxetan in men with metastatic castrate-resistant prostate cancer. This is an ASCO Meeting Abstract ...
Vepdegestrant introduces a novel mechanism in oncology: targeted protein degradation to remove cancer-driving proteins. This approach may overcome endocrine resistance, a key challenge in advanced ...
Conceptual overview of the vision-based ProTac sensing technology. ProTac can actively switch between proximity and tactile sensing modes, relying on input images captured by inner cameras and a soft ...
FDA has approved vepdegestrant (VEPPANU), the first PROTAC therapy, for adults with ESR1-mutated ER+/HER2- advanced or metastatic breast cancer after endocrine therapy progression. In VERITAC-2, vepde ...
A deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results